Published in PLoS One on October 31, 2011
Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One (2013) 0.85
Cholera toxin B: one subunit with many pharmaceutical applications. Toxins (Basel) (2015) 0.83
Streptococcus pneumoniae Transmission Is Blocked by Type-Specific Immunity in an Infant Mouse Model. MBio (2017) 0.75
Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques. Mucosal Immunol (2015) 0.75
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med (2003) 15.48
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet (2009) 15.31
Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med (2008) 7.79
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis (2007) 6.45
Mucosal immunity and vaccines. Nat Med (2005) 5.44
Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 4.41
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis (1996) 2.96
Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis (2002) 2.95
Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun (2000) 2.84
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Placental transport of immunoglobulin G. Vaccine (2003) 2.62
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest (1999) 2.61
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis (2000) 2.55
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med (2002) 2.32
Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol (1985) 2.20
Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest (2006) 2.16
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis (2000) 2.11
PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine (1996) 2.08
Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis (2004) 2.08
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology (1997) 1.99
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J (2004) 1.96
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine (2000) 1.82
Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J Immunol (1995) 1.81
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature (2008) 1.62
Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol (2011) 1.47
Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat. J Cell Biol (1990) 1.46
Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J (2007) 1.44
Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun (2005) 1.41
Serotype replacement in perspective. Vaccine (2009) 1.37
Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. Infect Immun (2009) 1.35
The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol (2004) 1.32
Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun (2007) 1.23
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol (1994) 1.23
Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis (2007) 1.22
Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine (2001) 1.20
Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci U S A (2003) 1.19
Antibody response to outer membrane protein of nontypeable Haemophilus influenzae in otitis-prone children. J Pediatr (1993) 1.18
Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol (2009) 1.18
The prevention of pneumococcal disease in children. N Engl J Med (2001) 1.15
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. J Immunol (2009) 1.12
Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis (2011) 1.10
Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist (2008) 1.07
Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol (2010) 1.06
Prospects for prevention of childhood infections by maternal immunization. Curr Opin Infect Dis (2006) 1.06
The mucosal immune system: features of inductive and effector sites to consider in mucosal immunization and vaccine development. Reg Immunol (1992) 1.05
Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. J Infect Dis (2007) 1.03
Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol (2010) 0.99
Antibody responses to the outer membrane protein P6 of non-typeable Haemophilus influenzae and pneumococcal capsular polysaccharides in otitis-prone children. Acta Otolaryngol (1999) 0.99
Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun (2002) 0.94
Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol (2008) 0.93
Placental transfer of IgG subclasses in a Japanese population. Pediatr Int (2000) 0.91
Serotype replacement in invasive pneumococcal disease: where do we go from here? J Infect Dis (2007) 0.89
Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines. Vaccine (2003) 0.89
Maternal immunization. Clin Infect Dis (1999) 0.89
Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. Vaccine (2009) 0.89
Immunoglobulin-secreting cells of maternal origin can be detected in B cell-deficient mice. Biol Reprod (2000) 0.88
Human antibodies to pneumococcal surface protein A in health and disease. Pediatr Infect Dis J (2000) 0.87
The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol (2004) 0.86
Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog (2010) 0.86
Natural materno-fetal transfer of antibodies to PspA and to PsaA. Clin Exp Immunol (2004) 0.84
Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA). J Infect Chemother (2008) 0.84
Immune response to surface protein A of Streptococcus pneumoniae and to high-molecular-weight outer membrane protein A of Moraxella catarrhalis in children with acute otitis media. J Infect Dis (2000) 0.83
Pneumococcal conjugate vaccines as maternal and infant immunogens: challenges of maternal recruitment. Vaccine (2003) 0.80
Maternal intranasal immunization with outer membrane protein P6 maintains specific antibody level of derived offspring. Vaccine (2006) 0.77
Maternal immunization to protect the mother and neonate. Expert Rev Vaccines (2005) 0.77
Genetic basis for the new pneumococcal serotype, 6C. Infect Immun (2007) 5.27
Evolutionary genetics of the capsular locus of serogroup 6 pneumococci. J Bacteriol (2004) 3.81
Basophils enhance immunological memory responses. Nat Immunol (2008) 3.35
Validation of a multiplex pneumococcal serotyping assay with clinical samples. J Clin Microbiol (2006) 2.48
Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis (2003) 2.46
PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol (2008) 2.42
Individual risk factors associated with nasopharyngeal colonization with Streptococcus pneumoniae and Haemophilus influenzae: a Japanese birth cohort study. Pediatr Infect Dis J (2013) 2.22
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Streptococcus pneumoniae forms surface-attached communities in the middle ear of experimentally infected chinchillas. J Infect Dis (2009) 2.10
Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity (2007) 2.07
Production of a unique pneumococcal capsule serotype belonging to serogroup 6. Microbiology (2009) 2.07
Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun (2004) 1.91
Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J (2010) 1.87
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun (2003) 1.70
Mn2+-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence. Infect Immun (2006) 1.55
Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun (2008) 1.54
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun (2004) 1.53
Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity (2002) 1.50
Treatment and outcome of severe and non-severe acute otitis media. Eur J Pediatr (2004) 1.45
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res (2002) 1.45
Macrophage Turnover Kinetics in the Lungs of Mice Infected with Streptococcus pneumoniae. Am J Respir Cell Mol Biol (2007) 1.42
Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J Immunol (2007) 1.41
Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun (2005) 1.41
The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J Immunol (2004) 1.37
Evolution and virulence of serogroup 6 pneumococci on a global scale. J Bacteriol (2002) 1.37
Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J Immunol (2009) 1.27
Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis (2005) 1.26
Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect Immun (2007) 1.25
Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect Immun (2010) 1.23
Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio (2012) 1.22
Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun (2005) 1.22
Lipoprotein PsaA in virulence of Streptococcus pneumoniae: surface accessibility and role in protection from superoxide. Infect Immun (2004) 1.21
Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol (2006) 1.20
Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci (2008) 1.19
Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci U S A (2003) 1.19
Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun (2003) 1.19
PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun (2007) 1.17
Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun (2003) 1.15
The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun (2010) 1.14
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology (2012) 1.13
Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun (2003) 1.09
FMS-like tyrosine kinase 3 ligand aggravates the lung inflammatory response to Streptococcus pneumoniae infection in mice: role of dendritic cells. J Immunol (2007) 1.06
Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines. Vaccine (2004) 1.04
Streptococcus pneumoniae sheds syndecan-1 ectodomains through ZmpC, a metalloproteinase virulence factor. J Biol Chem (2006) 1.03
Lysozyme M deficiency leads to an increased susceptibility to Streptococcus pneumoniae-induced otitis media. BMC Infect Dis (2008) 1.03
Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. J Infect Dis (2007) 1.03
Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma. Int J Cancer (2010) 1.02
Downregulation of TESTIN and its association with cancer history and a tendency toward poor survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2009) 1.02
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Nontypeable Haemophilus influenzae isolated from intractable acute otitis media internalized into cultured human epithelial cells. Auris Nasus Larynx (2009) 1.00
Characterization of a streptococcal cholesterol-dependent cytolysin with a lewis y and b specific lectin domain. Biochemistry (2008) 1.00
Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. J Clin Microbiol (2003) 1.00
Characterization of the dihydrolipoamide dehydrogenase from Streptococcus pneumoniae and its role in pneumococcal infection. Mol Microbiol (2002) 1.00
Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun (2005) 1.00
Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol (2010) 0.99
Determination of pneumococcal serotypes/genotypes in nasopharyngeal secretions of otitis media children by multiplex PCR. Eur J Pediatr (2007) 0.99
Effects of zinc deficiency and pneumococcal surface protein a immunization on zinc status and the risk of severe infection in mice. Infect Immun (2003) 0.99
A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine (2005) 0.99
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae. Antimicrob Agents Chemother (2009) 0.98
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. Antimicrob Agents Chemother (2007) 0.98
Streptococcus pneumoniae serotype 9A isolates contain diverse mutations to wcjE that result in variable expression of serotype 9V-specific epitope. J Infect Dis (2011) 0.97
Rapid diagnosis of pneumococcal meningitis: implications for treatment and measuring disease burden. Pediatr Infect Dis J (2005) 0.97
The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation. J Exp Med (2013) 0.97
CCL5 modulates pneumococcal immunity and carriage. J Immunol (2006) 0.96
Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniae. Antimicrob Agents Chemother (2011) 0.95
The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol (2012) 0.95
Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein a provides insight into microbial defense mechanism. J Mol Biol (2007) 0.95
Clinical and microbiological impact of human bocavirus on children with acute otitis media. Eur J Pediatr (2009) 0.94
Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect Immun (2010) 0.94
Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunol Med Microbiol (2009) 0.93
Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages. Infect Immun (2008) 0.93
Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci (2007) 0.93